More Good News in the Treatment of Multidrug-Resistant Pulmonary Tuberculosis

In a multinational open-label trial, an all-oral 9-month bedaquiline-containing regimen and a 6-month bedaquiline regimen with injectable kanamycin were superior to a 9-month control injectable regimen.

The incidence of resistant tuberculosis (TB) continues to rise worldwide, in part because treatment protocols are prolonged, complex, and painful, all potentially leading to medication failures. Several small single-nation studies have found that bedaquiline-based regimens appear effective for these infections (NEJM JW Infect Dis Mar 2020 and N Engl J Med 2020 382:893; NEJM JW Infect Dis Mar 2022 and Am J Respir Crit Care Med 2022; 205:1214; NEJM JW Infect Dis Sep 2022 and N Engl J Med 2022; 387:810). Now, investigators sponsored by USAID and the manufacturer of bedaquiline have performed a randomized, phase 3, noninferiority, unmasked study — STREAM stage 2 — on the treatment of multidrug-resistant TB in seven countries between March 2016 …

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

More Good News in the Treatment of Multidrug-Resistant Pulmonary Tuberculosis

Topics

Reviewing Author